According to Inflarx boss and founder Niels Riedemann, previous talks with the US authorities were very encouraging.
(Photo: InflaRx)
Frankfurt With two new developments from the biotech industry in the approval process at the US drug agency FDA, new therapy options for seriously ill Covid patients are emerging for the first time in almost two years. Both active ingredients showed survival advantages for Covid patients in clinical studies, but at the same time are subject to certain uncertainties as far as the validity of the data is concerned.
The first is the active substance Sabizabulin, which the US cancer research company Veru has submitted in Europe and the USA and which an advisory committee of the US Food and Drug Administration (FDA) will deal with on November 9th.
On the other hand, it is about the drug vilobelimab, for which the German biotech company Inflarx also applied for emergency approval from the FDA a few days ago. According to Inflarx boss and founder Niels Riedemann, previous talks with the US authorities were very encouraging. Discussions are being held with the European Medicines Agency Ema about a possible application for approval.
Few treatment options for severe cases
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue